Contrast-enhanced MR imaging of malignant brain tumors.
Magnetic resonance (MR) imaging was performed before and serially after intravenous injection of 1 mmol/kg gadolinium-DTPA (Schering) in 17 patients with clinical and histologic diagnosis of malignant cerebral tumors. There was a decrease of 1% in T1 and 10% in T2 in normal white matter and a decrease of 8% in T1 and 14% in T2 in normal gray matter. Contrast enhancement was observed in 16 of the 17 tumors. In the region of maximal enhancement a mean decrease of 16% in T1 was observed in low-grade gliomas, a mean decrease in T1 of 29% was seen in high-malignancy gliomas, and a mean decrease in T1 of 33% was observed in metastases. The decreases in T1 persisted for at least 50 min. In one case the central cystic region of the tumor displayed a decrease in T1 and T2. Measurements of signal intensity displayed maximal contrast enhancement with an IR 1500/500/44 sequence, much less with SE 1500/44, and least with SE 1500/80. Edema was observed on precontrast images in 14 cases, but satisfactory definition of the tumor-edema margin was only possible in four cases. After contrast enhancement this margin was defined in 10 cases. In four of the 17 cases areas of apparent "edema" seen before administration of Gd-DTPA displayed significant contrast enhancement and probably represented tumor infiltration. Comparison with CT showed a greater degree of contrast enhancement on MR images in eight cases, an equal degree in eight cases, and greater enhancement on CT in one case.(ABSTRACT TRUNCATED AT 250 WORDS)